In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seeing Machines' visual analyser:

This article was originally published in Clinica

Executive Summary

Imaging software firm Seeing Machines, of Canberra, Australia, has received 510(k) marketing clearance from the US FDA for its revolutionary new medical device, the TrueField Analyzer (TFA). The TFA aids the measurement of defects in a patient's visual field, a crucial step in the detection and management of diseases of the vision system, including glaucoma, age related macular degeneration and diabetic retinopathy. The device measures both eyes simultaneously, and the entire test of both eyes can be completed in around five minutes, including rest breaks within the test. US launch of the tool is expected later this year - Seeing Machines intends to exhibit the device at the upcoming annual meeting of the American Academy of Ophthalmology in New Orleans in November. The company received a grant of Aus$113,000 (US$90,376) from the Australian government in June 2006 to fund development of the device (see Clinica No 1209, p 12).

You may also be interested in...



Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Topics

UsernamePublicRestriction

Register

MT049494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel